Eleftheria (Ria) Kodosaki 👩🏻‍🔬🔬🧠

📢New in The Lancet Neurology! We validate a two-step blood test for Alzheimer’s disease: 1️⃣ plasma %p-tau217 identifies amyloid-β pathology 2️⃣ plasma eMTBR-tau243 assesses whether AD pathology is causing clinical symptoms 🔗sciencedirect.com/science/articl…

Why do women account for nearly 2/3rd of all cases of Alzheimer's disease? A new, thorough review @jclinicalinvest, open-access, on its origins in midlife. jci.org/articles/view/…

Elevated plasma #pTau181 and #NfL levels in #AlzheimerDisease patients largely reflect broad neuropsychiatric impairment rather than psychosis alone. ja.ma/4uf42qO

Can Alzheimer’s blood biomarkers work equally well across all populations. Join Natalia Chemas for this Research Showcase. …unities.dementiaresearcher.nihr.ac.uk/c/events/resea…

PU.1: the conductor of #Alzheimers symphony Chunli Sun & Qianjin Liu #microglia link.springer.com/article/10.118…

Head-to-head comparison of brain-derived pTau217 and total pTau217 for brain amyloid and tau pathology classification pnas.org/doi/abs/10.107…

Microglia protein profiles in CSF across Alzheimer’s disease clinical stages idp.nature.com/authorize?resp…

Multiple molecular mimics in Epstein Barr Nuclear Antigen-1, and the pathogenesis of multiple sclerosis pnas.org/doi/full/10.10…

How do blood-based biomarkers associate depressive symptoms and Alzheimer’s disease risk? #AlzResearch Key Details: 🩸11,947 non-demented adults ≥ 70 years 🩸Higher glial fibrillary acidic protein (GFAP) was associated with higher depressive symptoms alz-journals.onlinelibrary.wiley.com/doi/10.1002/al…

No single biomarker is enough! Watch the All Biomarkers Panel discussion recording from #AAICNeuro Neuroscience Next Manchester 👇 youtu.be/QLgmuJB8O_A

In #MajorDepressiveDisorder, shared brain and blood biomarkers indicate disrupted mitochondrial metabolism, neurodevelopment, inflammation, transcription, and apoptotic pathways, highlighting potential biomarker and treatment targets. 🔗 ja.ma/3ORnBVE

If Parkinson’s is “biologically defined” by a positive α-synuclein test, what do we do with the 10% who are negative? Can we distinguish between detecting pathology and defining disease? linkedin.com/posts/alberto-…

In #MajorDepressiveDisorder, shared brain and blood biomarkers indicate disrupted mitochondrial metabolism, neurodevelopment, inflammation, transcription, and apoptotic pathways, highlighting potential biomarker and treatment targets. 🔗 ja.ma/3OuX5RW

What accounts for the progression from healthy aging to Alzheimer's disease over an extended period of time? The critical role of the immune system, particularly T cells and microglia. A new, excellent review @ImmunityCP cell.com/immunity/fullt…

Please that our #AAICNeuro Manchester event is underway 😃

Now in @CellCellPress: We profiled cerebrospinal fluid proteomes from 5,000 neurology patients by mass spectrometry — mapping protein changes across stroke, brain cancer, infections & autoimmune diseases, revealing shared and disease-specific signatures. sciencedirect.com/science/articl…

Epigenomic subtypes of late-onset Alzheimer’s disease reveal distinct microglial signatures link.springer.com/article/10.100…

New @Nature The brains of Super Agers produce more neurons than people some 40 years younger, a neurogenesis resilient signature linked to exceptional cognitive health and memory skills nature.com/articles/s4158…

New Research Alert! 🚨 We’ve identified novel plasma proteins and metabolites linked to Alzheimer’s risk in both European and African ancestry groups. Most of these findings haven't been reported before! Full study in @ALZJournal: alz-journals.onlinelibrary.wiley.com/doi/10.1002/al…

Sex Differences in Amyloid Pathology by Race, Ancestry, and APOE ε 4 jamanetwork.com/journals/jaman…